Comparative Pharmacology
Head-to-head clinical analysis: FLURAZEPAM HYDROCHLORIDE versus TEMAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLURAZEPAM HYDROCHLORIDE versus TEMAZ.
FLURAZEPAM HYDROCHLORIDE vs TEMAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA by increasing the frequency of chloride channel opening.
Temazepam, a benzodiazepine, enhances the effect of gamma-aminobutyric acid (GABA) at the GABA-A receptor, increasing chloride ion conductance and causing neuronal hyperpolarization, leading to anxiolytic, sedative, and hypnotic effects.
15-30 mg orally at bedtime as a single dose for insomnia; maximum dose 30 mg/day.
Temazepam 15-30 mg orally at bedtime, up to 60 mg if needed.
None Documented
None Documented
Terminal elimination half-life: 40-114 hours (mean 74 hours); accumulates extensively with repeated dosing, leading to prolonged sedation.
Clinical Note
moderateTemazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Temazepam is combined with Fluticasone propionate."
Clinical Note
moderateTemazepam + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Temazepam."
Clinical Note
moderateTemazepam + Haloperidol
"The risk or severity of adverse effects can be increased when Temazepam is combined with Haloperidol."
Clinical Note
moderateTemazepam + Sulfisoxazole
Terminal elimination half-life: 1.5–2 hours; in severe renal impairment (CrCl <30 mL/min), half-life may extend to 4–6 hours, requiring dose adjustment.
Renal: 90% (as metabolites, <1% unchanged); Fecal: <10%; Biliary excretion minimal.
Renal: ~80% as unchanged drug and metabolites; biliary/fecal: ~20%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Sulfisoxazole can be decreased when combined with Temazepam."